In the past decades the incidence of colorectal cancer (CRC) in people under the age of 50
years has increased, which is referred to as early-onset CRC or young-onset CRC (YO …

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Bevacizumab plays an important role in the first and second line treatment for metastatic
colorectal cancer (CRC). And induction of hypoxia and the tumors response to it plays an …

Colorectal cancer (CRC) is still one of the most common types of cancer in the world, and
the gut microbiome plays an important role in its development. The microbiome is involved …

Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …

Abstract KRAS G12C mutation is prevalent in~ 4% of colorectal cancer (CRC) and is
associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest …

Background HER2 amplification has been identified in 2–3% of patients with colorectal
cancer, although there are currently no approved HER2-targeted therapies for colorectal …